• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ceapro Inc.

Aeterna Zentaris and Ceapro Complete Merger Transaction
June 03, 2024
From Ceapro Inc.
Via GlobeNewswire
Tickers AEZS CRPOF TSX-V:CZO TSX:AEZS
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
May 29, 2024
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
April 29, 2024
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
March 28, 2024
From Ceapro Inc.
Via GlobeNewswire
Tickers AEZS CRPOF TSX-V:CZO TSX:AEZS
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
February 26, 2024
From Ceapro Inc.
Via GlobeNewswire
Tickers AEZS CRPOF TSX-V:CZO TSX:AEZS
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
February 23, 2024
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
February 15, 2024
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
December 13, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
November 29, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
November 27, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
November 07, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
August 29, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
August 25, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
July 18, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro to Participate in the Virtual Investor Summer Spotlight Series
July 05, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Announces Results of 2023 Shareholders’ Meeting
June 07, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update
May 25, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases
May 23, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration
May 03, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations
April 27, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights
April 12, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference
March 23, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society
March 08, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company
February 21, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event
January 10, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Announces Grant of Stock Options
January 04, 2023
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets
December 22, 2022
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights
November 09, 2022
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets
November 07, 2022
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers
October 13, 2022
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap